|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. http://globocan.iarc.frApril 30–2014
|
|
2
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary
colorectal adenocarcinomas and their corresponding metastases. Clin
Cancer Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Custodio A and Feliu J: Prognostic and
predictive biomarkers for epidermal growth factor receptor-targeted
therapy in colorectal cancer: Beyond KRAS mutations. Crit
Rev Oncol Hematol. 85:45–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY,
Chen JZ, Ding H, Mao C and Tang JL: Promising biomarkers for
predicting the outcomes of patients with KRAS wild-type
metastatic colorectal cancer treated with anti-epidermal growth
factor receptor monoclonal antibodies: A systematic review with
meta-analysis. Int J Cancer. 133:1914–1925. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soeda H, Shimodaira H, Watanabe M, Suzuki
T, Gamoh M, Mori T, Komine K, Iwama N, Kato S and Ishioka C:
Clinical usefulness of KRAS, BRAF, and PIK3CA
mutations as predictive markers of cetuximab efficacy in
irinotecan- and oxaliplatin-refractory Japanese patients with
metastatic colorectal cancer. Int J Clin Oncol. 18:670–677. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
German S, Aslam HM, Saleem S, Raees A,
Anum T, Alvi AA and Haseeb A: Carcinogenesis of PIK3CA. Hered
Cancer Clin Pract. 11:52013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu K, Yan H, Wang R, Zhu H, Meng X, Xu X,
Dou X and Chen D: Mutations of KRAS and PIK3CA as
independent predictors of distant metastases in colorectal cancer.
Med Oncol. 31:162014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stintzing S and Lenz HJ: A small cog in a
big wheel: PIK3CA mutations in colorectal cancer. J Natl Cancer
Inst. 105:1775–1776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ikenoue T, Kanai F, Hikiba Y, et al:
Functional analysis of PIK3CA gene mutations in human colorectal
cancer. Cancer Res. 65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosty C, Young JP, Walsh MD, et al: PIK3CA
activating mutation in colorectal carcinoma: Associations with
molecular features and survival. PLoS ONE. 8:e654792013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen Y, Wang J, Han X, Yang H, Wang S, Lin
D and Shi Y: Effectors of epidermal growth factor receptor pathway:
The genetic profiling of KRAS, BRAF, PIK3CA, NRAS
mutations in colorectal cancer characteristics and personalized
medicine. PLoS ONE. 8:122013.
|
|
12
|
Soeda H, Shimodaira H, Watanabe M, Suzuki
T, Gamo M, Takahashi M, Komine K, Kato S and Ishioka C: KRAS
mutation in patients with metastatic colorectal cancer does not
preclude benefit from oxaliplatin-or irinotecan-based treatment.
Mol Clin Oncol. 2:356–362. 2014.PubMed/NCBI
|
|
13
|
Huang L, Liu Z, Deng D, Tan A, Liao M, Mo
Z and Yang X: Anti-epidermal growth factor receptor monoclonal
antibody-based therapy for metastatic colorectal cancer: A
meta-analysis of the effect of PIK3CA mutations in KRAS
wild-type patients. Arch Med Sci. 10:1–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: Revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stec R, Bodnar L, Charkiewicz R, et al:
K-Ras gene mutation status as a prognostic and predictive factor in
patients with colorectal cancer undergoing irinotecan- or
oxaliplatin-based chemotherapy. Cancer Biol Ther. 13:1235–1243.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Samuels Y, Wang Z, Bardelli A, et al: High
frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li VS, Wong CW, Chan TL, Chan AS, Zhao W,
Chu KM, So S, Chen X, Yuen ST and Leung SY: Mutations of PIK3CA in
gastric adenocarcinoma. BMC Cancer. 5:292005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on
the efficacy of cetuximab plus chemotherapy in
chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Razis E, Pentheroudakis G, Rigakos G, et
al: EGFR gene gain and PTEN protein expression are favorable
prognostic factors in patients with KRAS wild-type
metastatic colorectal cancer treated with cetuximab. J Cancer Res
Clin Oncol. 140:737–748. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tejpar S and Piessevaux H: Personalized
medicine in metastatic colorectal cancer treated with
anti-epidermal growth factor receptor agents: A future opportunity?
Asia Pac J Clin Oncol. 10:2–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Domagała P, Hybiak J, Sulżyc-Bielicka V,
Cybulski C, Ryś J and Domagała W: KRAS mutation testing in
colorectal cancer as an example of the pathologist's role in
personalized targeted therapy: A practical approach. Pol J Pathol.
63:145–164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ogino S, Nosho K, Kirkner GJ, et al:
PIK3CA mutation is associated with poor prognosis among patients
with curatively resected colon cancer. J Clin Oncol. 27:1477–1484.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herreros-Villanueva M, Gomez-Manero N,
Muñiz P, García-Girón C and Coma del Corral MJ: PIK3CA mutations in
KRAS and BRAF wild type colorectal cancer patients. A
study of Spanish population. Mol Biol Rep. 38:1347–1351. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cathomas G: PIK3CA in Colorectal Cancer.
Front Oncol. 4:352014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pentheroudakis G, Kotoula V, De Roock W,
et al: Biomarkers of benefit from cetuximab-based therapy in
metastatic colorectal cancer: Interaction of EGFR ligand expression
with RAS/RAF, PIK3CA genotypes. BMC Cancer. 13:492013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sartore-Bianchi A, Martini M, Molinari F,
et al: PIK3CA mutations in colorectal cancer are associated with
clinical resistance to EGFR-targeted monoclonal antibodies. Cancer
Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Prenen H, De Schutter J, Jacobs B, De
Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E and Tejpar
S: PIK3CA mutations are not a major determinant of resistance to
the epidermal growth factor receptor inhibitor cetuximab in
metastatic colorectal cancer. Clin Cancer Res. 15:3184–3188. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for
anti-EGFR treatment in metastatic colorectal cancer: A systematic
review and meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karapetis CS, Jonker D, Daneshmand M, et
al: NCIC Clinical Trials Group and the Australasian
Gastro-Intestinal Trials Group: PIK3CA, BRAF, and PTEN
status and benefit from cetuximab in the treatment of advanced
colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer
Res. 20:744–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ogino S, Liao X, Imamura Y, et al:
Alliance for Clinical Trials in Oncology: Predictive and prognostic
analysis of PIK3CA mutation in stage III colon cancer intergroup
trial. J Natl Cancer Inst. 105:1789–1798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liao X, Morikawa T, Lochhead P, et al:
Prognostic role of PIK3CA mutation in colorectal cancer: Cohort
study and literature review. Clin Cancer Res. 18:2257–2268. 2012.
View Article : Google Scholar : PubMed/NCBI
|
